KZR
Kezar Life Sciences, Inc.Price
Daily candles with volume.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since May 11. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q1 2026: 2 added (0 new), 1 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$1.255 → −$0.910 over 90 days. 1 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest +4.6% to 158.5K shares. 2.3 days to cover.
Who's buying
13F· Q1 2026| Fund | Move | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | $1.4M |
| FMR LLC | DOUBLED | $75.7K |
| UBS Group AG | TRIM | $96.00 |
| VANGUARD GROUP INC | ADD | $2.1M |
| STATE STREET CORP | ADD | $170.4K |
| TWO SIGMA INVESTMENTS, LP | TRIM | $71.2K |
| MORGAN STANLEY | TRIM | $35.8K |
| FMR LLC | NEAR_EXIT | $1.3K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Oct 2025| Date | Firm | Rating |
|---|---|---|
| Oct 17, 2025 | Jefferies DOWNGRADE | Hold |
| Oct 17, 2025 | William Blair DOWNGRADE | Market Perform |
| Oct 17, 2025 | Wells Fargo MAINTAIN | Equal-Weight |
| Jul 16, 2025 | HC Wainwright & Co. REITERATE | Neutral |
| Dec 19, 2024 | Wells Fargo MAINTAIN | Equal-Weight |
| Dec 2, 2024 | HC Wainwright & Co. REITERATE | Neutral |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Chiang Pichi Luo SVP, Corporate Controller May 11, 2026 | TO ISSUER | 7,999 sh |
Chiang Pichi Luo SVP, Corporate Controller May 11, 2026 | TO ISSUER | 4,999 sh |
Chiang Pichi Luo SVP, Corporate Controller May 11, 2026 | TO ISSUER | 2,899 sh |
Chiang Pichi Luo SVP, Corporate Controller May 11, 2026 | TO ISSUER | 2,499 sh |
Chiang Pichi Luo SVP, Corporate Controller May 11, 2026 | TO ISSUER | 2,401 sh |
Chiang Pichi Luo SVP, Corporate Controller May 11, 2026 | TO ISSUER | 599 sh |
Chiang Pichi Luo SVP, Corporate Controller May 11, 2026 | TO ISSUER | 2,052 sh |
Chiang Pichi Luo SVP, Corporate Controller May 11, 2026 | TO ISSUER | 1,199 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Next FY | -$3.96 | -$4.66–-$3.27 | -28.5% | $0.00 |
| Current Q | -$0.91 | -$0.91–-$0.91 | +27.5% | $0.00 |
| Current FY | -$4.02 | -$4.46–-$3.58 | -22.9% | $0.00 |
| Next Q | -$0.87 | -$0.87–-$0.87 | +29.6% | $0.00 |
Short side
FINRA· Apr 30, 2026SecBot reports
3 filings · 0 bullish · 1 bearish · 2 neutral- BEARISH EFFECTMay 15, 2026
Kezar Life Sciences' registration statement on Form S-3 (File No. 333-284712) was declared…
The effective shelf registration introduces a persistent dilution overhang. Monitor for any subsequent takedown announcements (e.g., prospectus supplement or 424B filing) which would indicate an…
- NEUTRAL 25-NSEMay 11, 2026
Nasdaq filed a 25-NSE notification to remove Kezar Life Sciences' common stock from listing…
No further trading on Nasdaq; shareholders who have not tendered shares should do so promptly. Monitor for any CVR valuation developments.
- NEUTRAL 8-KMay 11, 2026
Kezar Life Sciences has been acquired by Aurinia Pharma U.S., Inc. in a completed tender offer and…
The acquisition is complete, KZR shares will cease trading and be deregistered. The CVR represents the only remaining upside for former shareholders, tied to future milestones. Monitor Aurinia…
All KZR filing & press-release reports (3)
- EFFECT reportMay 15, 2026
- 25-NSE reportMay 11, 2026
- 8-K reportMay 11, 2026